📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells. (2023)

First Author: Tanasescu R

Attributed to: AI gets real: using routine clinical data and Artificial Intelligence to predict worsening of Multiple Sclerosis despite treatment (AIMS) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s40120-023-00539-9

PubMed Identifier: 37715885

Publication URI: http://europepmc.org/abstract/MED/37715885

Type: Journal Article/Review

Volume: 12

Parent Publication: Neurology and therapy

Issue: 6

ISSN: 2193-6536